Viridian Therapeutics, Inc.\DE (CIK: 0001590750) EDGAR, Information, Filings... CompaniesBIO.Com

Viridian Therapeutics, Inc.\DE

Mailing address
203 CRESCENT STREET, BLDG. 17, SUITE 102B, WALTHAM, Delaware, 02453
Phone
617.272.4600
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
8071 - (CF Office: Office of Life Sciences) SERVICES-MEDICAL LABORATORIES
Filings
N/A

Viridian Therapeutics, Inc.\DE (CIK: 0001590750) is an American company incorporated in the state of Massachusetts. Head office is located at 203 CRESCENT STREET, BLDG. 17, SUITE 102B, WALTHAM, Massachusetts, 02453. Work in the industry 8071 - (CF Office: Office of Life Sciences) SERVICES-MEDICAL LABORATORIES. Viridian Therapeutics, Inc.\DE is a public company and trade via Over-The-Counter (OTC).

Old names:

MIRAGEN THERAPEUTICS, INC. from 2017-13-Feb to 2021-15-Jan
SIGNAL GENETICS, INC. from 2013-06-Dec to 2017-10-Feb
SIGNAL GENETICS LLC from 2013-12-Nov to 2014-09-Jul

Owner	Filings	Transaction Date	Type of Owner
Myers Scott Dunseth	0001356256	Feb-06-2023	director, officer: Chief Executive Officer
Melvin Carrie	0001935199	Jun-21-2022	officer: COO
Meisner Lara	0001883986	Oct-01-2021	officer: General Counsel and Secretary
Frazier Life Sciences Public Fund, L.P.	0001863769	Aug-16-2021	10 percent owner
FHMLSP, L.L.C.	0001879465	Aug-16-2021	10 percent owner
FHMLSP, L.P.	0001879466	Aug-16-2021	10 percent owner
Humer Kristian	0001872280	Jul-26-2021	officer: CFO and CBO
Moses Jennifer K.	0001706667	Jul-14-2021	director
TURNER JOSEPH L	0001266129	Feb-04-2021	director
Morris Arlene	0001362520	Feb-04-2021	director
Hatfield Jeffrey S.	0001609879	Feb-04-2021	director
Leverone Jason A.	0001692747	Jan-18-2021	officer: Chief Financial Officer
Katz Barrett	0001841628	Jan-18-2021	officer: Chief Medical Officer
Escolar Diana	0001797269	Jan-15-2021	officer: Former Chief Medical Officer
Rauch Lee M.	0001815345	Jan-15-2021	other: See Remarks
RA Capital Healthcare Fund LP	0001315082	Dec-07-2020	10 percent owner
RA CAPITAL MANAGEMENT, L.P.	0001346824	Dec-07-2020	10 percent owner
Kolchinsky Peter	0001384859	Dec-07-2020	10 percent owner
Shah Rajeev M.	0001619841	Dec-07-2020	10 percent owner
COHEN STEVEN A/SAC CAPITAL MGMT LP	0000905226	Nov-10-2020	10 percent owner
Point72 Asset Management, L.P.	0001603466	Nov-10-2020	10 percent owner
Point72 Capital Advisors, Inc.	0001698049	Nov-10-2020	10 percent owner
Logos Global Master Fund LP	0001831371	Nov-04-2020	10 percent owner
Harwin Peter Evan	0001663607	Oct-27-2020	director
Fairmount Healthcare Fund L.P.	0001686157	Oct-27-2020	director, other: See Remarks
Violin Jonathan	0001730615	Oct-27-2020	officer: President and COO
Fairmount Healthcare Fund II L.P.	0001769651	Oct-27-2020	director, other: See Remarks
Fairmount Funds Management LLC	0001802528	Oct-27-2020	director, other: See Remarks
Kiselak Tomas	0001830177	Oct-27-2020	director
Fairmount Healthcare Fund II GP LLC	0001830382	Oct-27-2020	director, other: See Remarks
Fairmount Healthcare Fund GP LLC	0001830383	Oct-27-2020	director, other: See Remarks
Marshall William Stuart	0001693127	Oct-15-2020	other: See Remarks
Bowden Christopher	0001608601	Aug-10-2017	director
KOCH KEVIN	0001185829	Feb-13-2017	director
LEFKOFF KYLE	0001191818	Feb-13-2017	director
RUBIN PAUL D	0001210905	Feb-13-2017	officer: EVP, Research & Development
Atlas Venture Fund VII L P	0001346450	Feb-13-2017	10 percent owner
Booth Bruce	0001451612	Feb-13-2017	director
Hughes Thomas E.	0001611048	Feb-13-2017	director
Remeditex Ventures LLC	0001627363	Feb-13-2017	10 percent owner
Creecy John W	0001689143	Feb-13-2017	director
Levy Adam Scott	0001693134	Feb-13-2017	officer: Chief Business Officer
Gonyer David A	0001578768	Feb-08-2017	director
LEBOW BENNETT S	0001005790	Feb-03-2017	director, 10 percent owner
Smith Robin L	0001365035	Feb-03-2017	director
Riccitelli Samuel D	0001414839	Nov-19-2015	director, officer: President & CEO
Schuling Douglas A	0001414837	Aug-06-2015	director
SEYMOUR TAMARA A	0001288232	Aug-04-2015	officer: CFO, Secretary, Treasurer
Johnson Robert Brian	0001591139	Jun-17-2014	officer: CFO and CAO
LEBOW ALPHA, LLLP	0001610518	Jun-17-2014	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Viridian Therapeutics, Inc.\DE

Filings	Format	Description	Filed/Effective	File/Film Number
8-K	Document	Current report filing Acc-no: 0001193125-25-004435 (34 Act) Size: KB	Jan-10-2025	001-36483 25522876
8-K	Document	Current report filing Acc-no: 0001193125-24-279021 (34 Act) Size: KB	Dec-16-2024	001-36483 241550131
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-119344 (34 Act) Size: KB	Nov-14-2024	005-88625 241464817
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-119339 (34 Act) Size: KB	Nov-14-2024	005-88625 241464806
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001193125-24-258738 (34 Act) Size: KB	Nov-14-2024	005-88625 241463743
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001104659-24-119033 (34 Act) Size: KB	Nov-14-2024	005-88625 241463302
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001590750-24-000023 (34 Act) Size: KB	Nov-12-2024	001-36483 241443252
8-K	Document	Current report filing Acc-no: 0001193125-24-255130 (34 Act) Size: KB	Nov-12-2024	001-36483 241443251
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000093751-24-000893 (34 Act) Size: KB	Oct-18-2024	005-88625 241379671
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-110485 ( Act) Size: 0 KB	Sep-30-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-110484 ( Act) Size: 0 KB	Sep-30-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-24-100769 ( Act) Size: 0 KB	Sep-17-2024
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001104659-24-100768 (34 Act) Size: KB	Sep-17-2024	005-88625 241306009
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-24-218405 (33 Act) Size: KB	Sep-13-2024	333-267351 241296391
8-K	Document	Current report filing Acc-no: 0001193125-24-218131 (34 Act) Size: KB	Sep-12-2024	001-36483 241295836
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0001193125-24-216641 (33 Act) Size: KB	Sep-10-2024	333-267351 241290388
8-K	Document	Current report filing Acc-no: 0001193125-24-216321 (34 Act) Size: KB	Sep-10-2024	001-36483 241288741
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0001193125-24-198865 (33 Act) Size: KB	Aug-12-2024	333-281478 241196770
8-K	Document	Current report filing Acc-no: 0001193125-24-196513 (34 Act) Size: KB	Aug-08-2024	001-36483 241186213
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001590750-24-000019 (34 Act) Size: KB	Aug-08-2024	001-36483 241186140

Recent 20 filings. View all Viridian Therapeutics, Inc.\DE filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Viridian Therapeutics, Inc.\DE overview
Viridian Therapeutics, Inc.\DE job
Viridian Therapeutics, Inc.\DE stock
Viridian Therapeutics, Inc.\DE ownership
Viridian Therapeutics, Inc.\DE CEO
Viridian Therapeutics, Inc.\DE documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.